Try DISQOVER

CHALLENGES IN NEW TARGET IDENTIFICATION

By integrating information from internal, public, and third-party sources in a highly efficient manner, DISQOVER greatly speeds up this process. Identifying new targets typically involves carefully scrutinizing large volumes of information from various sources to look for biological evidence, including reports from previous drug tests that target specific genes, publications, grants, and much more. The analysis of this information can lead to the identification of new targets that have not previously been considered. This essentially means looking at data and sources from a different angle or point-of-view, which in turn provides fresh insights into potential leads for future drug development efforts. The process of identifying a new target is time-consuming and very costly. Typically, creating just one report involves a multidisciplinary team poring over data from 20 to 40 sources.

 

A TOUCH OF DISQOVER

With DISQOVER, we have created a solution that can identify potential new targets for disease treatment. The system is based on our proprietary technology, which is able to analyze millions of data points from internal and external sources in order to generate relevant information.  By gathering these fragmented sources – internal, public, and third-party – into a holistic, easily searchable interface, DISQOVER makes finding the right knowledge, evidence, and supporting data significantly more efficient. As a result, researchers spend less time searching, and organizations can identify new targets more quickly and with greater accuracy – giving them a crucial competitive edge.

 

DISQOVER FOR PRIORITY-SETTING

Our knowledge platform can also be used to help prioritize treatments: once you’ve identified a new target, DISQOVER can help you determine what kind of data you need and how best to obtain it. This allows researchers to focus their efforts on the most promising approaches.

 

ADVANTAGES OF DISQOVER FOR NEW TARGET IDENTIFICATION

  • Search third-party, internal, and public data sources for biological evidence, drug test results, publications, grants, and more – all via a single location.
  • Easily gather information, evidence, and supporting data and make highly accurate new target identification reports faster.
  • Accelerate the identification process and get a head start over your competition.

get in touch with our team to schedule
a personalized demo.

Let's chat

WHITEPAPER

DATA-DRIVEN CLINICAL TRIAL FEASIBILITY & STUDY DESIGN

How a new approach to data management can boost efficiency and lead to better decision-making in drug development.

Download
Book-img-new